Effect of HMG-CoA reductase inhibition on endothelial dysfunction-inducing protein in hypercholesterolemic rabbits;Efecto de la inhibición de la HMG-CoA reductasa sobre la proteína inductora de disfunción endotelial en conejos hipercolesterolémicos

Revista Espanola de Cardiologia

Volumn 55, Issue 11, 2002, Pages 1151-1158

  Jiménez, Ana M ^a   Millás, Inmaculada ^a   Farré, Jeónimo ^a   García Méndez, Antonio ^a   Jiménez, Petra ^a   Arriero, María M ^a   García Colis, Elena ^a   de Andrés, Raimundo ^a   Gomez, Juan ^a   Casado, Santos ^a   López Farré, Antonio ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Endothelium; Hypercholesterolemia; mRNA; Nitric oxide

Indexed keywords

ACETYLCHOLINE; CELL PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; NITRIC OXIDE SYNTHASE; SIMVASTATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLOOD VESSEL WALL; CELL CULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; ENDOTHELIUM CELL; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; RABBIT; RNA STABILITY; UPREGULATION; VASCULAR ENDOTHELIUM; VASODILATATION; ANIMAL; BIOSYNTHESIS; ENZYMOLOGY; GENETICS; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ENDOTHELIUM, VASCULAR; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; RABBITS; RNA, MESSENGER; SIMVASTATIN; VASODILATION;

EID: 0036857460     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(02)76778-x     Document Type: Article

References (23)

1. Moncada S, Higgs A. The L-arginine nitric oxide pathway. N Engl J Med 1993;329:2002-12.
2. Sessa WC. The nitric oxide synthase family of proteins. J Vasc Res 1194;31:131-43.
3. Busse R, Mulsch A, Fleming I, Hecker M. Mechanisms of nitric release from the vascular endothelium. Circulation 1993;87:18-25.
4. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in humans: effects of age, atherosclerosis, hypercholesterolemia and hypertension. J Clin Invest 1993;92:652-62.
5. Chappell SP, Lewis MJ, Henderson AH. Effect of lipid feeding on endothelium-dependent relaxation in rabbit aortic preparations. Cardiovasc Res 1987;21:34-8.
6. Osborne JA, Siegman MJ, Sedar AW, Mooers SU, Lefer AM. Lack of endothelium-dependent relaxation in coronary resistance arteries of cholesterol-feed-rabbits. Am J Physiol 1989;256: C591-C7.
7. Yoshizumi M, Perella MA, Burnett JC, Lee ME. Tumor necrosis factor downregulates and endothelial nitric oxide synthase mRNA by shotening its half-life. Circ Res 1993;73:205-9.
8. Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995;270:319-24.
9. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-35.
10. Jackson RJ. Cytoplasmic regulation of mRNA function: the importance of the 3'-untranslated region. Cell 1993;74:9-14.
11. Zhon B, Malter JS. Regulation of mRNA stability and its relevance to disease. Lab Invest 1991;65:610-21.
12. Alonso J, Sánchez de Miguel L, Montón M, Casado S, López-Farré A. Endothelial cytosolic proteins bind to the 3'-untranslated region of endothelial nitric oxide synthase mRNA: regulation by tumor necrosis alpha. Mol Cell Biol 1997;17:5719-26.
13. De Frutos T, de Miguel L, García Durán M, González-Fernández F, Rodríguez-Feo JA, Montón M, et al. Expression of an endothelial-type nitric oxide synthase isoform in human neutrophils: modification by tumor necrosis factor-alpha during acute myocardial infarction. J Am Coll Cardiol 2001;37:800-7.
14. Treasure CB, Klein JL, Weintranb WS, Talley JD, Stillabower ME, Kosinski AS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
15. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy an endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:483-8.
16. Gallego MJ, García-Villalón S, López-Farré, A, García JL, Garrón MP, Gómez B, et al. Mechanisms of the endothelial toxocity of cyclosporine A (CyA). Circ Res 1994;74:477-84.
17. De Frutos T, Sánchez de Miguel L, García-Durán M, González-Fernández F, Rodríguez-Feo JA, Montón M, et al. Nitric oxide generated by smooth muscle cells decreases nitric synthase expression in coincubated endothelial cells: involvement of TNF-α. Am J Physiol 1999;277:H1317-H25.
18. Cernadas MR, Sánchez de Miguel L, García-Durán M, González-Fernández F, Millás I, Montón M, et al. Expression of constitutive and indicible nitric oxide synthases in the vascular wall of young and aging rats. Circ Res 1998;83:279-86.
19. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
20. Müllner EW, Kühn LC. A stem-loop in the 3'-untranslated region mediacts iron-dependent regulation of transferrin receptor mRNA stability. Cell 1989;53:815-25.
21. González-Fernández F, Jiménez A, López-Blaya A, Velasco S, Arriero M, Celdrán A, et al. Cerivastatin prevents tumor necrosis factor-α-induced downregulation of endothelial nitric oxide synthase: role of endothelial cytosolic proteins. Atherosclerosis 2001;155:61-70.
22. Laufs U, Liao JK. Post-transcripcional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPasa. J Biol Chem 1998;273:24266-71.
23. Stokes KY, Clanton EC, Rwsell JM, Ross CR, Granger DN. NAD(P) H oxidase-derived superoxide mediats hypercholesterolemia-induced leukocyte-endothelial adhesion. Circ Res 2001;88: 499-505.